Elevara Medicines Raises $70 Million Series A to Advance Phase 2 Rheumatoid Arthritis Trial and Expand Pipeline
Globenewswire·2025-10-22 07:00
Co-led by Forbion and Sofinnova Partners, along with founding investor Monograph Capital, and WeatherdenInnovative lead program, ELV001, in-licensed by Elevara from Japan’s Teijin Pharma with good tolerability and safety, plus early signs of efficacy in Phase 1bDisrupting the treatment paradigm for patients with incomplete response to Standard of Care (Methotrexate + Tumor Necrosis Factor inhibitors (TNFi)) London, UK – 22 October 2025 – Elevara Medicines (“Elevara”), a clinical-stage biotech developing the ...